Shuttle Pharmaceuticals
Shuttle Pharmaceuticals
SHPH
NASDAQ
1.93
USD
124.42%
About
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy.
Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers.
SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 30.7K |
| Three Month Average Volume | 989.4K |
| High Low | |
| Fifty-Two Week High | 6.42 USD |
| Fifty-Two Week Low | 1.81 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 30 Aug 2024 |
| Price and Volume | |
| Current Price | 1.93 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -38.28% |
| Thirteen Week Relative Price Change | -57.55% |
| Twenty-Six Week Relative Price Change | -42.31% |
| Fifty-Two Week Relative Price Change | -73.98% |
| Year-to-Date Relative Price Change | -55.23% |
| Price Change | |
| One Day Price Change | 4.61% |
| Thirteen Week Price Change | -54.57% |
| Twenty-Six Week Price Change | -36.56% |
| Five Day Price Change | -16.45% |
| Fifty-Two Week Price Change | -67.39% |
| Year-to-Date Price Change | -46.98% |
| Month-to-Date Price Change | -39.67% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.01913 USD |
| Book Value Per Share (Most Recent Quarter) | 1.31344 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.01913 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.31344 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.92703 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.53509 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.79146 USD |
| Normalized (Last Fiscal Year) | -3.2792 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.53509 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.79146 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.53509 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.79146 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.72003 USD |
| Cash Per Share (Most Recent Quarter) | 1.99187 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.53143 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.75332 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.80281 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -46.07% |
| EPS Change (Trailing Twelve Months) | -90.85% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -3,246,480 |
| Net Debt (Last Fiscal Year) | -4,732,550 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 3 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -5,600,200 |
| Free Cash Flow (Trailing Twelve Months) | -5,482,250 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -50 |
| Net Interest Coverage (Trailing Twelve Months) | -5 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 18 |
| Total Debt to Equity (Most Recent Quarter) | 34 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -90.28% |
| Return on Assets (Trailing Twelve Months) | -96.75% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -112.37% |
| Return on Equity (Trailing Twelve Months) | -152.02% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -104.75% |
| Return on Investment (Trailing Twelve Months) | -119.37% |
| Return on Investment (5 Year) | -99,999.99% |